8FB.F FACEPHI BIOMETRIA EO-04
- Market cap
- -
- P/E
- -
- P/B
- 2.98x
- ROE
- 1.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 8FB.F undervalued?
Graham numberThe Graham number of FACEPHI BIOMETRIA EO-04 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
FACEPHI BIOMETRIA EO-04 fundamental analysis
No fundamental analysis for FACEPHI BIOMETRIA EO-04 yet.
FACEPHI BIOMETRIA EO-04 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
FACEPHI BIOMETRIA EO-04 financial statements
FACEPHI BIOMETRIA EO-04 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 13.2M | 22.3M | 25.2M | 28.9M | 36.0M |
| Gross Profit | 13.5M | 13.6M | 14.8M | 13.2M | 22.7M |
| Operating Income | -412K | 2.58M | -4.07M | -6.02M | 3.63M |
| EBITDA | - | 3.30M | -564K | -220K | 7.90M |
| Net Income | -554K | 1.11M | -4.31M | -8.88M | 369K |
| EPS | -0.04 | 0.06 | -0.20 | -0.35 | 0.01 |
| Balance Sheet | |||||
| Total Assets | 18.4M | 32.3M | 45.7M | 49.7M | 48.0M |
| Total Liabilities | 9.65M | 17.0M | 25.7M | 30.5M | 26.2M |
| Shareholders' Equity | 8.71M | 15.2M | 20.0M | 19.2M | 21.8M |
| Cash & Short-term Investments | 1.34M | 1.89M | 2.45M | 5.52M | 1.89M |
| Cash Flow | |||||
| Operating Cash Flow | -3.60M | -5.82M | 853K | 724K | 7.34M |
| Capital Expenditure | 2.55M | 2.07M | 9.86M | 5.25M | 8.77M |
| Free Cash Flow | -6.15M | -7.88M | -9.01M | -4.53M | -1.42M |
| Ratios | |||||
| ROE | -6.4% | 7.3% | -21.5% | -46.3% | 1.7% |
| ROA | -3.0% | 3.4% | -9.4% | -17.9% | 0.8% |
| Net Profit Margin | -4.2% | 5.0% | -17.1% | -30.8% | 1.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
FACEPHI BIOMETRIA EO-04 dividends
FACEPHI BIOMETRIA EO-04 has not paid dividends in the last 5 fiscal years.
Who owns FACEPHI BIOMETRIA EO-04
Ownership data of FACEPHI BIOMETRIA EO-04 is not available yet.
FACEPHI BIOMETRIA EO-04 company profile
- Company name
- FACEPHI BIOMETRIA EO-04
- Ticker
- 8FB.F
- ISIN
- ES0105029005
- Exchange
- Frankfurt Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -